EGFR-Blockade mit Gefitinib. Erfolge beim NSCLC

Publisher： Karger

E-ISSN： 2296-5262|27|3|322-323

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.3, 2004-07, pp. : 322-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

EGFR-Blockade. Neue Therapieoption für solide Tumoren

By  

Oncology Research and Treatment, Vol. 27, Iss. 2, 2004-05 ,pp. : 216-217

Karger

Access to resources Recommend Favorite

EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients

By  

Oncology Research and Treatment, Vol. 31, Iss. 4, 2008-03 ,pp. : 174-178

Karger

Access to resources Recommend Favorite

Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 12, 2015-12 ,pp. : 2947-2958

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overcoming Resistance to EGFR Inhibitors in NSCLC

By  

Reviews on Recent Clinical Trials, Vol. 11, Iss. 2, 2016-06 ,pp. : 99-105

Bentham Science Publishers

Access to resources Recommend Favorite

Histologie-basierter Algorithmus der molekularen Diagnostik des epidermalen Wachstumsfaktor-Rezeptorgens (Epidermal Growth Factor Receptor, EGFR) beim nicht-kleinzelligen Lungenkarzinom (non-small cell lung cancer, NSCLC) *

By Popper Helmut  

Wiener klinische Wochenschrift, Vol. 123, Iss. 9-10, 2011-05 ,pp. : 316-321

Springer Publishing Company

Access to resources Recommend Favorite